Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer

Journal of Clinical Oncology

Volumn 23, Issue 30, 2005, Pages 7445-7453

  Avril, Norbert ^a   Sassen, Stefanie ^a   Schmalfeldt, Barbara ^a   Naehrig, Joerg ^a   Rutke, Stephan ^a   Weber, Wolfgang A ^a   Werner, Martin ^a   Graeff, Henner ^a   Schwaiger, Markus ^a   Kuhn, Walther ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; FLUORODEOXYGLUCOSE F 18; FUROSEMIDE; PACLITAXEL; SCOPOLAMINE BUTYL BROMIDE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC IMAGING; DRUG METABOLISM; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT THERAPY; METHODOLOGY; OVARY TUMOR; PREDICTION AND FORECASTING; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SCINTISCANNING; SURVIVAL RATE;

ADULT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RISK FACTORS; SURVIVAL RATE;

EID: 32944461277     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.965     Document Type: Article

References (49)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 351:2519-2529, 2004
2. Park TW, Kuhn WC: Neoadjuvant chemotherapy in ovarian cancer. Expert Rev Anticancer Ther 4:639-647, 2004
3. Hoskins WJ: Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 71:1534-1540, 1993
4. Schwartz PE, Rutherford TJ, Chambers JT, et al: Neoadjuvant chemotherapy for advanced ovarian cancer: Long-term survival. Gynecol Oncol 72:93-99, 1999
5. Vergote I, De Wever I, Tjalma W, et al: Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients. Gynecol Oncol 71:431-436, 1998
6. Kuhn W, Rutke S, Spathe K, et al: Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92:2585-2591, 2001
7. Morice P, Dubernard G, Rey A, et al: Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg 197:955-963, 2003
8. Fanfani F, Ferrandina G, Corrado G, et al: Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology 65:316-322, 2003
9. Jacob JH, Gershenson DM, Morris M, et al: Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 42:146-150, 1991
10. Schwartz PE, Chambers JT, Makuch R: Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 53:33-37, 1994
11. Avril N: GLUT1 expression in tissue and F-18 FDG uptake. J Nucl Med 45:930-932, 2004
12. Römer W, Avril N, Dose J, et al: Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose. Rofo 166:62-68, 1997
13. Fenchel S, Grab D, Nuessle K, et al: Asymptomatic adnexal masses: Correlation of FDG PET and histopathologic findings. Radiology 223:780-788, 2002
14. Rohren EM, Turkington TG, Coleman RE: Clinical applications of PET in oncology. Radiology 231:305-332, 2004
15. Wahl RL, Zasadny K, Helvie M, et al: Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 11:2101-2111, 1993
16. Romer W, Hanauske AR, Ziegler S, et al: Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 91:4464-4471, 1998
17. Schelling M, Avril N, Nährig J, et al: Positron emission tomography using [F-18]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689-1695, 2000
18. Smith IC, Welch AE, Hutcheon AW, et al: Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676-1688, 2000
19. Weber WA, Ott K, Becker K, et al: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058-3065, 2001
20. Flamen P, Van Cutsem E, Lerut A, et al: Positron emission tomography for assessment of the response to induction chemotherapy in locally advanced esophageal cancer. Ann Oncol 13:361-368, 2002
21. Ott K, Fink U, Becker K, et al: Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: Results of a prospective trial. J Clin Oncol 21:4604-4610, 2003
22. Wieder HA, Brucher BL, Zimmermann F, et al: Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22:900-908, 2004
23. McCluggage WG, Lyness RW, Atkinson RJ, et al: Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol 55:27-31, 2002
24. Weber WA, Ziegler SI, Thodtmann R, et al: Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40:1771-1777, 1999
25. Weber WA, Petersen V, Schmidt B, et al: Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21:2651-2657, 2003
26. Downey RJ, Akhurst T, Ilson D, et al: Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: Results of a prospective trial. J Clin Oncol 21:428-432, 2003
27. Mac Manus MP, Hicks RJ, Matthews JP, et al: Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21:1285-1292, 2003
28. Minn H, Zasadny KR, Quint LE, et al: Lung cancer: Reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 196:167-173, 1995
29. Ansquer Y, Leblanc E, Clough K, et al: Neoadjuvant chemotherapy for unresectable ovarian carcinoma: A French multicenter study. Cancer 91:2329-2334, 2001
30. Bridgewater JA, Nelstrop AE, Rustin GJ, et al: Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 17:501-508, 1999
31. Rustin GJ: Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials. J Clin Oncol 21:187-193, 2003
32. Rustin GJ, Nelstrop AE, Bentzen SM, et al: Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 18:1733-1739, 2000
33. Gronlund B, Hansen HH, Hogdall C, et al: Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? Br J Cancer 90:377-382, 2004
34. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
35. Spaepen K, Stroobants S, Dupont P, et al: Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414-419, 2001
36. Stroobants S, Goeminne J, Seegers M, et al: 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39:2012-2020, 2003
37. Kawamoto S, Urban BA, Fishman EK: CT of epithelial ovarian tumors. Radiographics Spec No.:S263-S264, 1999
38. Townsend DW, Carney JP, Yap JT, et al: PET/CT today and tomorrow. J Nucl Med 45 (Suppl 1):4S-14S, 2004
39. O'Connell M: PET-CT modification of RECIST guidelines. J Natl Cancer Inst 96:801-802, 2004
40. Salzer-Kuntschik M, Brand G, Delling G: Determination of the degree of morphological regression following chemotherapy in malignant bone tumors. Pathologe 4:135-141, 1983
41. Honkoop AH, Pinedo HM, De Jong JS, et al: Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 107:211-218, 1997
42. Becker K, Mueller JD, Schulmacher C, et al: Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98:1521-1530, 2003
43. Shimizu D, Ishikawa T, Ichikawa Y, et al: Current progress in the prediction of chemosensitivity for breast cancer. Breast Cancer 11:42-48, 2004
44. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-791, 2004
45. Schwartz DR, Kardia SL, Shedden KA, at al: Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62:4722-4729, 2002
46. van 't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
47. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002
48. Selvanayagam ZE, Cheung TH, Wei N, et al: Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genet Cytogenet 154:63-66, 2004
49. Spentzos D, Levine DA, Ramoni MF, et al: Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22:4700-4710, 2004